Neurogene Inc. Files 8-K for Disclosure and Exhibits
Ticker: NGNE · Form: 8-K · Filed: Jun 21, 2024 · CIK: 1404644
Sentiment: neutral
Topics: disclosure, financials, corporate-action
Related Tickers: NGNE
TL;DR
Neurogene Inc. (NGNE) filed an 8-K on 6/21/24 for disclosures and financials.
AI Summary
Neurogene Inc. filed an 8-K on June 21, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neoleukin Therapeutics, Inc., is based in New York, NY, and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing provides important updates and financial information for investors and stakeholders of Neurogene Inc., formerly Neoleukin Therapeutics.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically contains disclosures and exhibits, and does not indicate any immediate material changes or risks.
Key Numbers
- 001-36327 — SEC File Number (Identifies the company's filing with the SEC.)
- 98-0542593 — IRS Number (Company's Employer Identification Number.)
Key Players & Entities
- Neurogene Inc. (company) — Registrant
- Neoleukin Therapeutics, Inc. (company) — Former Name
- June 21, 2024 (date) — Date of Report
- 535 W 24th Street, 5th Floor New York, NY 10011 (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Neurogene Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on June 21, 2024.
What was Neurogene Inc. formerly known as?
Neurogene Inc. was formerly known as Neoleukin Therapeutics, Inc.
What is the business address of Neurogene Inc.?
The business address of Neurogene Inc. is 535 W 24th Street, 5th Floor, New York, NY 10011.
In which industry sector does Neurogene Inc. operate?
Neurogene Inc. operates in the Pharmaceutical Preparations sector, SIC code 2834.
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-06-21 08:32:30
Key Financial Figures
- $0.000001 — ange on which registered Common Stock, $0.000001 par value NGNE The Nasdaq Global Market
Filing Documents
- ngne-20240621.htm (8-K) — 26KB
- june2024ngnecorporatepre.htm (EX-99.1) — 40KB
- june2024ngnecorporatepre001.jpg (GRAPHIC) — 101KB
- june2024ngnecorporatepre002.jpg (GRAPHIC) — 255KB
- june2024ngnecorporatepre003.jpg (GRAPHIC) — 96KB
- june2024ngnecorporatepre004.jpg (GRAPHIC) — 65KB
- june2024ngnecorporatepre005.jpg (GRAPHIC) — 108KB
- june2024ngnecorporatepre006.jpg (GRAPHIC) — 127KB
- june2024ngnecorporatepre007.jpg (GRAPHIC) — 66KB
- june2024ngnecorporatepre008.jpg (GRAPHIC) — 36KB
- june2024ngnecorporatepre009.jpg (GRAPHIC) — 113KB
- june2024ngnecorporatepre010.jpg (GRAPHIC) — 110KB
- june2024ngnecorporatepre011.jpg (GRAPHIC) — 85KB
- june2024ngnecorporatepre012.jpg (GRAPHIC) — 85KB
- june2024ngnecorporatepre013.jpg (GRAPHIC) — 86KB
- june2024ngnecorporatepre014.jpg (GRAPHIC) — 80KB
- june2024ngnecorporatepre015.jpg (GRAPHIC) — 92KB
- june2024ngnecorporatepre016.jpg (GRAPHIC) — 122KB
- june2024ngnecorporatepre017.jpg (GRAPHIC) — 98KB
- june2024ngnecorporatepre018.jpg (GRAPHIC) — 154KB
- june2024ngnecorporatepre019.jpg (GRAPHIC) — 131KB
- june2024ngnecorporatepre020.jpg (GRAPHIC) — 90KB
- june2024ngnecorporatepre021.jpg (GRAPHIC) — 99KB
- june2024ngnecorporatepre022.jpg (GRAPHIC) — 39KB
- june2024ngnecorporatepre023.jpg (GRAPHIC) — 78KB
- june2024ngnecorporatepre024.jpg (GRAPHIC) — 88KB
- june2024ngnecorporatepre025.jpg (GRAPHIC) — 94KB
- june2024ngnecorporatepre026.jpg (GRAPHIC) — 106KB
- june2024ngnecorporatepre027.jpg (GRAPHIC) — 36KB
- june2024ngnecorporatepre028.jpg (GRAPHIC) — 85KB
- june2024ngnecorporatepre029.jpg (GRAPHIC) — 69KB
- june2024ngnecorporatepre030.jpg (GRAPHIC) — 30KB
- june2024ngnecorporatepre031.jpg (GRAPHIC) — 117KB
- june2024ngnecorporatepre032.jpg (GRAPHIC) — 81KB
- june2024ngnecorporatepre033.jpg (GRAPHIC) — 90KB
- june2024ngnecorporatepre034.jpg (GRAPHIC) — 110KB
- june2024ngnecorporatepre035.jpg (GRAPHIC) — 119KB
- june2024ngnecorporatepre036.jpg (GRAPHIC) — 77KB
- june2024ngnecorporatepre037.jpg (GRAPHIC) — 85KB
- 0001404644-24-000080.txt ( ) — 5034KB
- ngne-20240621.xsd (EX-101.SCH) — 2KB
- ngne-20240621_lab.xml (EX-101.LAB) — 22KB
- ngne-20240621_pre.xml (EX-101.PRE) — 13KB
- ngne-20240621_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On June 21, 2024, Neurogene Inc. posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 attached hereto is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information or Exhibit 99.1 be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Corporate Presentation (June 2024) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROGENE INC. Date: June 21, 2024 By: /s/ Christine Mikail Name: Christine Mikail Title: President, Chief Financial Officer